Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis

Pereson, Matías J.; Amaya, Lucas; Neukam, Karin; Baré, Patricia; Echegoyen, Natalia; Badano, María Noel; Lucero, Alicia; Martelli, Antonella; García, Gabriel; Videla, Cristina; Martínez, Alfredo P.; Lello, Federico A. Di

doi:10.1016/j.cmi.2022.05.009

Cited by 16 publications

(28 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding previous infection with SARS-CoV-2, a significant correlation was found between higher anti-S-RBD IgG titers and a confirmed past infection for both the SpV/SpV and SpV/MOD schemes, with a notable difference (11 times) for the heterologous scheme. This finding is in accordance with our previously reported values for the same vaccination schemes [12-], for the sputnik V homologous scheme [29-30-] and for RNAm vaccines [35-].…”

Section: Discussionsupporting

confidence: 93%

“…There is little data on SpV/SpV or SpV/Mod reactogenicity under dialysis conditions and this work offers a contribution to the understanding of SARS-CoV-2 vaccination in this setting. In our sample, adverse events including local and systemic symptoms were higher in dialyzed patients who received the SpV/Mod scheme as we have previously described for the general population [12-]. In agreement with other studies, fatigue and myalgia were the most frequent systemic reactions [12-,39-].…”

Section: Discussionsupporting

confidence: 90%

“…The higher trend in the rate of adverse events in the SpV/Mod group was expected since it is well proven that stronger side effects were associated with mRNA vaccines in the general population [11-,12-27-40-,41-. It is important to note that the frequency of adverse events was lower than that observed in the general population and no patients required medical support [12-]. However, the median age of the sample analyzed in the present work was higher and the effect of age on reactogenicity has already been described in previous studies [4-,5-,42-].…”

Section: Discussionmentioning

confidence: 90%

“…In our sample, adverse events including local and systemic symptoms were higher in dialyzed patients who received the SpV/Mod scheme as we have previously described for the general population [12-]. In agreement with other studies, fatigue and myalgia were the most frequent systemic reactions [12-,39-]. The higher trend in the rate of adverse events in the SpV/Mod group was expected since it is well proven that stronger side effects were associated with mRNA vaccines in the general population [11-,12-27-40-,41-.…”

Section: Discussionmentioning

confidence: 93%

“…Fortunately, effective vaccination schemes against SARS-CoV-2 inducing reduction of both infection and the risk of severe COVID-19 have been rapidly developed [4-7-]. Moreover, when facing first dose serious adverse effects or dose supply shortcomings, introduced heterologous vaccination schemes have shown promising results [8-12-]. Nevertheless, clinical trials do not provide information about vaccine efficacy in dialysis populations and possible differences in immunogenicity among SARS-CoV-2 vaccination schemes are poorly understood due to their novelty.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

Laham

Martínez

Gimenez

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction: The humoral response to vaccines is the most used tool to evaluate the protection against SARS-CoV-2 infection. Dialysis patients are a high-risk population and have a reduced immune response to vaccination. Objective: To assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. Methods: SARS-CoV-2 anti-spike IgG (RBD) concentration was estimated 3-16 weeks after complete vaccination. Reactogenicity was evaluated until day 7 by patients self-reported side events. Results: 107 participants were enrolled [n=84 homologous (SpV/SpV), n=23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50-75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection (p=0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288-5680) BAU/mL] than in the homologous scheme [447 (100-1551) BAU/mL], p=0.022. In a linear model adjusted for age and gender, previous SARS-COV-2 infection (B: 1944.3; CI95: 1136.2-2753.4; p<0.001), and SpV/Mod vaccination scheme (B: 1241.5; CI95: 420.39-2062.6; p=0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. Conclusion: The present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good efficacy and safety under dialysis conditions. These results could be useful for future vaccination strategies, especially aimed at this risk group.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

Laham

Martínez

Gimenez

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

What makes SARS‐CoV‐2 unique? Focusing on the spike protein

Qian,

Zhang,

Wang

et al. 2024

Cell Biology International

View full text Add to dashboard Cite

Severe acute respiratory syndrome‐related coronavirus 2 (SARS‐CoV‐2) seriously threatens public health and safety. Genetic variants determine the expression of SARS‐CoV‐2 structural proteins, which are associated with enhanced transmissibility, enhanced virulence, and immune escape. Vaccination is encouraged as a public health intervention, and different types of vaccines are used worldwide. However, new variants continue to emerge, especially the Omicron complex, and the neutralizing antibody responses are diminished significantly. In this review, we outlined the uniqueness of SARS‐CoV‐2 from three perspectives. First, we described the detailed structure of the spike (S) protein, which is highly susceptible to mutations and contributes to the distinct infection cycle of the virus. Second, we systematically summarized the immunoglobulin G epitopes of SARS‐CoV‐2 and highlighted the central role of the nonconserved regions of the S protein in adaptive immune escape. Third, we provided an overview of the vaccines targeting the S protein and discussed the impact of the nonconserved regions on vaccine effectiveness. The characterization and identification of the structure and genomic organization of SARS‐CoV‐2 will help elucidate its mechanisms of viral mutation and infection and provide a basis for the selection of optimal treatments. The leaps in advancements regarding improved diagnosis, targeted vaccines and therapeutic remedies provide sound evidence showing that scientific understanding, research, and technology evolved at the pace of the pandemic.

show abstract

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background and Aim Dialysis patients are a high-risk population and have a reduced immune response to vaccination against SARS-CoV-2. The aim of this study was to assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. The vaccination scheme depended on dose availability and the prioritization of risk populations as established by the Argentine Ministry of Health. Methods Previous COVID-19 infection was determined in symptomatic patients. Binding IgG antibodies against the spike (S) receptor-binding domain (RBD) of SARS-CoV-2 (anti-S-RBD) concentration was assessed between 3 and 16 weeks after the boost dose. Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody units (BAU), a correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL equals 0.142 AU, as previously established by Abbott with the WHO international standard NIBSC 20–136. Following the manufacturer’s recommendations, samples were considered reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protective effect (PROT-80) against symptomatic SARS-CoV-2 infection was assumed when anti-S-RBD titers were 506 BAU/ml or higher. Charlson Comorbidity Index (CCI) score was classified as mild = 1–2, moderate = 3–4, and severe ≥ 5. Side effects were evaluated until day 7 by patients´ self-reported questionnaire. Results One hundred seven participants were enrolled [ n = 84 homologous (SpV/SpV), nn 23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50–75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection ( p = 0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288–5680) BAU/mL] than in the homologous scheme [447 (100–1551) BAU/mL], p = 0.022. In a linear model adjusted for age, gender, days from first vaccination to boost dose and days from the boost dose to the anti-S-RBD IgG determination, previous SARS-COV-2 infection (B: 2062.2; CI95: 1231.8–2892.6; p < 0.001), and SpV/Mod vaccination scheme (B: 1294.6; CI95: 435.58–2147.6; p = 0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. Conclusions The present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good e...

show abstract

Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis

Cited by 16 publications

References 22 publications

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

What makes SARS‐CoV‐2 unique? Focusing on the spike protein

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

Contact Info

Product

Resources

About